Cross-Bridged Macrocyclic Chelators for Metal Ion Kinetic Inertness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current metal chelates used in biomedical applications, such as MRI contrast agents and radiopharmaceuticals, face challenges in maintaining stability and kinetic inertness, particularly in vivo, where they are exposed to competing biogenic chelators and metal ions.
Innovation Solution
The development of new macrocyclic chelators that form a bridge after metal ion complexation, using a cycloaddition reaction between alkyne and azide substituents, creating a rigid structure and enhancing kinetic inertness up to 6 orders of magnitude compared to DOTA analogues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional macrocyclic chelators like DOTA are used, then metal complexation is achieved, but kinetic inertness is insufficient under in-vivo conditions
Solution Approach 1:
The patent combines macrocyclic chelator structure with cross-bridging elements to create composite chelating agents. The cross-bridges form additional coordination bonds with metal ions, creating a composite coordination sphere that significantly enhances kinetic inertness while maintaining thermodynamic stability. This composite approach allows the chelator to resist dissociation under in-vivo conditions better than conventional DOTA alone.
Solution Approach 2:
The chelator is divided into distinct functional segments: the macrocyclic ring providing base coordination, pendant arms for additional binding, and cross-bridging units that connect opposite sides of the ring. This segmentation allows each component to contribute specifically to metal binding, with cross-bridges providing the critical kinetic stabilization by creating a more rigid, locked structure that prevents metal ion release.
2Reliability
If rigid macrocyclic structures are used to increase kinetic inertness, then metal ion escape is reduced, but synthesis complexity increases
Solution Approach 1:
The patent develops a universal platform of macrocyclic chelators with standardized cross-bridging modules that can be applied to multiple metal ions (Ln(III), Act(III), Cu(II), Zn(II), etc.). The core macrocyclic structure with pendant arms and cross-bridges serves multiple functions: coordination, rigidification, and kinetic stabilization across different metal types, reducing the need for metal-specific optimization while maintaining high kinetic inertness.
3Reliability
If cross-bridged macrocyclic chelators are used, then kinetic inertness is enhanced, but synthesis difficulty increases
Solution Approach 1:
The patent employs preliminary action by pre-organizing the macrocyclic structure with pendant arms positioned to facilitate subsequent cross-bridging. The initial macrocyclization and pendant arm attachment are performed first, creating a pre-positioned framework that ready the molecule for cross-bridge formation. This stepwise preliminary preparation simplifies the overall synthesis by breaking down the complex cross-bridged structure construction into manageable sequential steps rather than attempting to form the complete structure in one step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These chelators achieve extremely high kinetic inertness, allowing them to act as efficient molecular traps for metal ions, maintaining stability under harsh hydrolytic conditions and preventing metal ion release in vivo, thus avoiding potential toxicity.
Implementation Method 1
macrocyclic compounds suitable as cross-bridged chelators for complexation of rare earth elements and/or s-, p-, d-block metals, forming extremely stable coordination compounds
Implementation Method 2
using a cycloaddition reaction between alkyne and azide substituents, creating a rigid structure
Data Source
AI summary
The present invention relates to compounds of general formula (I) for use as complexing agents. The invention further relates to the coordination compounds thereof, peptide conjugates, method of their preparation and use thereof.